Valneva's IXCHIQ® Vaccine Authorized in Canada for Ages 12 and Older

Valneva SE announced Health Canada's authorization of its chikungunya vaccine, IXCHIQ®, for individuals 12 years of age and older. This decision expands the initial authorization granted to adults, similar to the extension obtained in Europe for adolescents. Data submitted to Health Canada demonstrate prolonged antibody persistence over 24 months in 97% of participants.

Dr. Juan Carlos Jaramillo emphasized the importance of covering all age groups, as chikungunya spreads to previously unaffected areas. Through a partnership with CEPI, Valneva hopes to expand access to its vaccine in low- and middle-income countries.

As a reminder, IXCHIQ® was the first chikungunya vaccine approved in Brazil. This approval in Canada could facilitate other global approvals.